爱瑞森（人，小鼠，大鼠）酶联试剂盒 Irisin (Human, Mouse, Rat) ELISA Kit
产品名称：爱瑞森（人，小鼠，大鼠）酶联试剂盒
英文名称： Irisin (Human, Mouse, Rat) ELISA Kit
产品编号：SK00170-08
规格： 96 T
厂家：Aviscera Bioscience
产品介绍：
美国爱威斯生物开发的高灵敏度爱瑞森（人，小鼠，大鼠）酶联试剂盒
Irisin,a secreted myokine, is a circulating biomarker for metabolic syndrome. This new Irisin elisa kit was formulated by the glycosylated human irisin derived from HEK293 cells and specific monoclonal antibody. The antibody was validated by the glycosylated human irisin derived from HEK293 cells and human serum samples on western blot.
Citations:
-
Gonzalez-Gil AM, et al. Myokine-adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome. Diabetol Metab Syndr. 2019 Aug 5;11:63. doi: 10.1186/s13098-019-0458-2. eCollection 2019
-
Ewa Śliwicka et al. "Serum irisin and myostatin levels after 2 weeks of high-altitude climbing" https://doi.org/10.1371/journal.pone.0181259
-
Dr. Zheng-ping Zhang, et al. Serum irisin associates with breast cancer to spinal metastasis. Medicine (2018) 97:17
-
Dr. Zhu Li, et al. The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients. Biosci Rep. 2017 Jun 30; 37(3): BSR20170213.
Features
-
Irisin (Human) ELISA Kit
Code: SK00170-08
Size: 96 T
Standard Range: 0.8-51.2 ng/ml
Sensitivity: 75-100 pg/ml
Specificity: Human, Mouse, Rat, Bovine
Calibration: human Irisin derived from human cells
Sample Type: serum, plasma
Dilution Factor: 8~32
Sample Requires: 100 ul per well
Intra-CV: 4-6%
Inter-CV: 8-10%
Protocol: PDF
Antibody was validated by human Irisin derived HEK293 cells on WB
上图引用自文章：Gonzalez-Gil AM, et al. Myokine-adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome. Diabetol Metab Syndr. 2019 Aug 5;11:63. doi: 10.1186/s13098-019-0458-2. eCollection 2019,并标注中文汉字以便阅读。
